SCHEMBL3890352

SCHEMBL3890352

Cc1cnc2[nH]c3ccccc3c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.52
PDK4 Q16654 1/20 0.52
KIF11 P52732 1/20 0.50
GABRP O00591 4/20 0.49
GABRD O14764 4/20 0.49
GABRA1 P14867 4/20 0.49
GABRB1 P18505 4/20 0.49
GABRG2 P18507 4/20 0.49
GABRB3 P28472 4/20 0.49
GABRA5 P31644 4/20 0.49
GABRA3 P34903 4/20 0.49
GABRA2 P47869 4/20 0.49
GABRB2 P47870 4/20 0.49
GABRA4 P48169 4/20 0.49
GABRE P78334 4/20 0.49
GABRA6 Q16445 4/20 0.49
GABRG1 Q8N1C3 4/20 0.49
GABRG3 Q99928 4/20 0.49
GABRQ Q9UN88 4/20 0.49
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29990938 1.00 PDK2 (0.52) PDK2PDK4KIF11GABRPGABRD
SCHEMBL28280007 0.84 ACHE (0.54) PDK2PDK4KIF11GABRPGABRD
SCHEMBL678718 0.82 MMP2 (0.50) KIF11GABRPGABRDGABRA1GABRB1
SCHEMBL4414274 0.81 BCHE (0.50) PDK2PDK4GABRA1GABRG2GABRB3
SCHEMBL674512 0.80 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL16257468 0.80 NR1I3 (0.50) KIF11TDO2
SCHEMBL15999445 0.79 CA5A (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15318812 0.79 CHEK1 (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL13598869 0.78 PDK2 (0.43) PDK2PDK4GABRPGABRDGABRA1
SCHEMBL20685571 0.78 CHUK (0.47) PDK2PDK4MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931669-A1 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2008-06-18 EP claimed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 WO claimed
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed
WO-2009129401-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 WO disclosed
EP-2081930-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2009-07-29 EP disclosed
EP-2079696-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2009-07-22 EP disclosed
EP-1931669-A1 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2008-06-18 EP disclosed
WO-2008054956-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-05-08 WO disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 WO disclosed
WO-2008016184-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-07 WO disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF XDH, F7, CYP4X1 PDK2 178/4885PDK4 212/4885KIF11 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.